CAMP4 Therapeutics Corporation (CAMP)
CAMP trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$3.43
-6.28% on the day
Market cap
$215.2M
Micro cap
Revenue · 2025
$3.5M
+436.5% on 2024
Net income · 2025
-$80.4M
-2298.5% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | CAMP on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2024 |
| SEC CIK | 0001736730 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $3.5M |
| Net income | -$80.4M |
| Operating income | -$52.6M |
| Net margin | -2298.5% |
| Operating margin | -1502.4% |
| Revenue growth | +436.5% |
| Cash | $109.5M |
| Total assets | $117.8M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 61.5× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2026-08-12 |
| Latest annual report | 10-K | 2026-03-05 |
| Latest quarterly / interim | 10-Q | 2026-08-13 |
| Latest current report | 8-K | 2026-09-28 |
| Latest proxy | DEFA14A | 2026-04-23 |
Source: SEC EDGAR submissions feed, 189 recent filings. All filings on EDGAR.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ADCT | ADC Therapeutics SA Common Shares | $1.70 | -8.60% | $217.0M |
| EVMN | Evommune Inc. | $5.88 | -2.81% | $213.4M |
| AKBA | Akebia Therapeutics Inc. | $0.7700 | -2.56% | $213.4M |
| MGNX | MacroGenics Inc. | $3.42 | -8.06% | $217.9M |
| PYXS | Pyxis Oncology Inc. | $1.85 | -7.96% | $221.2M |
| SIGA | SIGA Technologies Inc. | $3.08 | -2.53% | $221.3M |
| PRQR | ProQR Therapeutics N.V. | $1.48 | -8.64% | $208.9M |
| KROS | Keros Therapeutics Inc. | $11.23 | -3.27% | $222.7M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier